Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Trevi Therapeutics

Trevi Therapeutics (NASDAQ: TRVI) insider transactions

In the twelve months to 10 November 2026, executives and directors of Trevi Therapeutics reported 4 open-market sales of 39,473 shares ($595,806) and 0 open-market purchases, by 1 person, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 19 most recent transactions in Trevi Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
15 September 2026Heffernan Michael ThomasDirectorOption exercise, 10b5-1 plan+18,421$3.0424,772Form 4
15 September 2026Heffernan Michael ThomasDirectorOpen-market sale, 10b5-1 plan−18,321$15.096,451Form 4
15 September 2026Heffernan Michael ThomasDirectorOpen-market sale, 10b5-1 plan−100$15.886,351Form 4
15 September 2026Heffernan Michael ThomasDirectorOption exercise, 10b5-1 plan+21,052$3.3327,403Form 4
15 September 2026Heffernan Michael ThomasDirectorOpen-market sale, 10b5-1 plan−20,952$15.096,451Form 4
15 September 2026Heffernan Michael ThomasDirectorOpen-market sale, 10b5-1 plan−100$15.886,351Form 4
2 December 2025Galletta ChristopherSee RemarksOption exercise+4,225$0.5126,095Form 4
25 March 2025Sciascia ThomasChief Scientific OfficerOption exercise+2,631$1.43224,004Form 4
25 March 2025Sciascia ThomasChief Scientific OfficerOpen-market sale−2,631$6.60221,373Form 4
21 March 2025Good Jennifer LPresident & CEOOption exercise+5,263$1.43218,576Form 4
21 March 2025Good Jennifer LPresident & CEOOpen-market sale−5,263$6.58213,313Form 4
10 March 2025Simon FarrellChief Commercial OfficerOption exercise+17,500$3.2163,150Form 4
10 March 2025Simon FarrellChief Commercial OfficerOption exercise+63,813$3.91126,963Form 4
10 March 2025Simon FarrellChief Commercial OfficerOption exercise+31,250$0.51158,213Form 4
10 March 2025Simon FarrellChief Commercial OfficerOpen-market sale−76,963$6.7381,250Form 4
10 March 2025Simon FarrellChief Commercial OfficerOpen-market sale−4,350$7.1576,900Form 4
8 January 2025Delfini LisaChief Financial OfficerOption exercise+5,000$0.5164,660Form 4
7 January 2025Delfini LisaChief Financial OfficerOption exercise+1,000$0.5159,660Form 4
13 December 2024Galletta ChristopherSee RemarksOption exercise+15,000$0.5119,935Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Trevi Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.